Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259376 · ClinicalTrials.gov registry record · Phase 3
American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm
A Phase 3 study of Atrial Fibrillation and Atrial Flutter, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 629
- Enrollment target
- 5
- Study locations
NCT00259376: Completed Phase 3 study of Atrial Fibrillation and Atrial Flutter, sponsored by Sanofi.
NCT00259376 is a Phase 3 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Sanofi. The registered enrollment target is 629 participants, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00259376, a Phase 3 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 629 participants
- Enrollment target
- 5
- Study locations
Study Summary
To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL). To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence. To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Dronedarone (SR33589)
Study Locations (5)
Other
- Sanofi-Aventis Administrative Office - Buenos Aires
- sanofi-aventis Australia administrative office - Macquarie Park
- Sanofi-Aventis Administrative Office - Laval
- Sanofi-Aventis Administrative Office - Midrand
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2001-11 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
What the finished NCT00259376 record still lists
NCT00259376 is an interventional study that assigns participants to a tested intervention. The registered 629 participants enrollment target is mid-sized for trials with a published cap, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00259376 lists 5 locations in 2 states (Other, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00259376 about?
NCT00259376 is a clinical study titled "American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm". To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL). To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/...
What is the current status of trial NCT00259376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 629 participants. The study started on 2001-11. Estimated completion is 2003-09.
What conditions does trial NCT00259376 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT00259376?
The interventions under investigation include: placebo (DRUG), Dronedarone (SR33589) (DRUG).
Who is sponsoring clinical trial NCT00259376?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00259376 being conducted?
This trial has 5 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00259376's enrollment target sits among peer trials
629 48th of 202 higher than 155 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia